

# Brian Lee Claggett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4414334/publications.pdf>

Version: 2024-02-01

274  
papers

22,106  
citations

12303

69  
h-index

10424

139  
g-index

300  
all docs

300  
docs citations

300  
times ranked

20044  
citing authors

#	ARTICLE	IF	CITATIONS
1	Spironolactone for Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2014, 370, 1383-1392.	13.9	1,993
2	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 2247-2257.	13.9	1,856
3	Angiotensinâ€“Nepriylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
4	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation</i> , 2015, 131, 34-42.	1.6	758
5	Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 447-456.	1.2	591
6	Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. <i>Lancet Public Health</i> , The, 2018, 3, e419-e428.	4.7	506
7	Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 2380-2385.	0.8	501
8	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2016, 37, 455-462.	1.0	396
9	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015, 132, 402-414.	1.6	371
10	Effect of the angiotensin-receptor-nepriylsin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015, 36, 1990-1997.	1.0	335
11	Heart failure with midâ€“range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	2.9	295
12	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 489-498.	1.9	272
13	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 333-340.	5.5	258
14	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
15	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002763.	1.6	224
16	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	1.6	218
17	Retinal Vessel Calibers in Predicting Long-Term Cardiovascular Outcomes. <i>Circulation</i> , 2016, 134, 1328-1338.	1.6	204
18	The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans. <i>New England Journal of Medicine</i> , 2015, 372, 21-29.	13.9	202

#	ARTICLE	IF	CITATIONS
19	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1217-1225.	2.9	195
20	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1096-1103.	2.9	194
21	Spirolactone Metabolites in TOPCAT â€” New Insights into Regional Variation. <i>New England Journal of Medicine</i> , 2017, 376, 1690-1692.	13.9	186
22	Sexâ€specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 535-542.	2.9	184
23	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. <i>JAMA Oncology</i> , 2017, 3, 1692.	3.4	179
24	On the Restricted Mean Survival Time Curve in Survival Analysis. <i>Biometrics</i> , 2016, 72, 215-221.	0.8	176
25	Machine learningâ€based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2019, 21, 74-85.	2.9	175
26	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGMâ€HF trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1228-1234.	2.9	173
27	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in PatientsâWith HFrEF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 795-806.	1.2	173
28	Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. <i>Circulation</i> , 2020, 142, 2080-2082.	1.6	168
29	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. <i>Annals of Internal Medicine</i> , 2015, 163, 127-134.	2.0	162
30	Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist. <i>Circulation: Heart Failure</i> , 2014, 7, 573-579.	1.6	155
31	Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 510-517.	2.9	153
32	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. <i>JAMA Cardiology</i> , 2017, 2, 79.	3.0	143
33	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1264-1272.	1.2	139
34	Echocardiographic Features of PatientsâWith HeartâFailure and PreservedâLeft Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2858-2873.	1.2	138
35	Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort. <i>Circulation</i> , 2015, 132, 1329-1337.	1.6	137
36	Temporal Trends in the Population Attributable Risk for Cardiovascular Disease. <i>Circulation</i> , 2014, 130, 820-828.	1.6	135

#	ARTICLE	IF	CITATIONS
37	Heart Failure Stages Among Older Adults in the Community. <i>Circulation</i> , 2017, 135, 224-240.	1.6	135
38	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 666.	3.0	130
39	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002744.	1.6	130
40	Angiotensin Receptor–Nephrilysin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	13.9	130
41	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 241-252.	1.9	129
42	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.	2.9	129
43	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 547-554.	5.5	124
44	Effectively Selecting a Target Population for a Future Comparative Study. <i>Journal of the American Statistical Association</i> , 2013, 108, 527-539.	1.8	123
45	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 590-595.	1.6	123
46	Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. <i>Circulation</i> , 2021, 143, 761-763.	1.6	118
47	Lung Ultrasound in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 849-858.	1.9	116
48	Influenza Vaccine in Heart Failure. <i>Circulation</i> , 2019, 139, 575-586.	1.6	114
49	Influenza Vaccination in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 152-158.	1.9	112
50	The frailty syndrome and outcomes in the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1570-1577.	2.9	106
51	Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults. <i>Circulation</i> , 2017, 135, 426-439.	1.6	99
52	Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	98
53	Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 363.	3.0	97
54	Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan. <i>New England Journal of Medicine</i> , 2015, 373, 2289-2290.	13.9	92

#	ARTICLE	IF	CITATIONS
55	Distinct neural representations of placebo and nocebo effects. <i>NeuroImage</i> , 2015, 112, 197-207.	2.1	91
56	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
57	Efficacy of Sacubitril/Valsartan Relative to A Prior Decompensation. <i>JACC: Heart Failure</i> , 2016, 4, 816-822.	1.9	84
58	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1199-1208.	2.2	83
59	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2015, 36, 939-945.	1.0	82
60	Right Atrial Function in Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, e003521; discussion e003521.	1.3	81
61	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
62	Left atrial structure and function in cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1128-1137.	0.5	80
63	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq1 1 0.784314 rgBT /Over	1.6	80
64	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78
65	Are All Placebo Effects Equal? Placebo Pills, Sham Acupuncture, Cue Conditioning and Their Association. <i>PLoS ONE</i> , 2013, 8, e67485.	1.1	78
66	Insulin Resistance and Incident Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 531-536.	1.9	77
67	Sleep Apnea Is Associated with Subclinical Myocardial Injury in the Community. The ARIC-SHHS Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1460-1465.	2.5	77
68	Role of Bâ€Type Natriuretic Peptide and Nâ€Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
69	Declining Lung Function and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1109-1122.	1.2	74
70	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1369-1379.	1.6	74
71	Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. <i>Circulation: Heart Failure</i> , 2016, 9, e001937.	1.6	71
72	Right Ventricular Function, Right Ventricularâ€Pulmonary Artery Coupling, and Heart Failure Risk in 4 US Communities. <i>JAMA Cardiology</i> , 2018, 3, 939.	3.0	71

#	ARTICLE	IF	CITATIONS
73	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 1174-1180.	0.5	70
74	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015, 8, 1052-1058.	1.6	70
75	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.	2.9	70
76	Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease. <i>Circulation: Heart Failure</i> , 2015, 8, 448-454.	1.6	68
77	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 689-697.	1.9	68
78	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 664-675.	1.9	68
79	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis. <i>JAMA Cardiology</i> , 2019, 4, 466.	3.0	68
80	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 671-677.	2.9	67
81	Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. <i>European Heart Journal</i> , 2012, 33, 1137-1141.	1.0	66
82	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018, 138, 570-577.	1.6	66
83	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 39.	3.8	65
84	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015, 36, 669-675.	1.0	62
85	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.	1.0	61
86	Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1763-1773.	1.2	61
87	Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities). <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	59
88	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 26.	3.0	59
89	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Tj ETQq1 1 0,784314 ggBT /Over 11, e004446.	1.6	58
90	Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1238-1243.	2.9	56

#	ARTICLE	IF	CITATIONS
91	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1701-1709.	2.9	56
92	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. <i>JACC: Heart Failure</i> , 2020, 8, 844-855.	1.9	56
93	Smoking and Cardiac Structure and Function in the Elderly. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004950.	1.3	55
94	Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2016, 374, 1094-1096.	13.9	55
95	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. <i>Circulation: Heart Failure</i> , 2018, 11, e004745.	1.6	55
96	Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. <i>Circulation</i> , 2015, 132, 1979-1989.	1.6	54
97	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. <i>Circulation</i> , 2022, 145, 1592-1604.	1.6	54
98	Racial Differences in Circulating Natriuretic Peptide Levels: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	53
99	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	52
100	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.	2.9	52
101	Ferritin levels and risk of heart failure—the Atherosclerosis Risk in Communities Study. <i>European Journal of Heart Failure</i> , 2017, 19, 340-347.	2.9	51
102	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019, 7, 25-32.	1.9	51
103	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2015, 17, 301-312.	2.9	50
104	Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). <i>Gastrointestinal Endoscopy</i> , 2013, 77, 624-630.	0.5	49
105	Lack of Association Between Heart Failure and Incident Cancer. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1501-1510.	1.2	49
106	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 313-320.	0.7	49
107	Heart Failure Risk Across the Spectrum of Ankle-Brachial Index. <i>JACC: Heart Failure</i> , 2014, 2, 447-454.	1.9	46
108	Prehypertension Is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study. <i>American Journal of Hypertension</i> , 2016, 29, 568-574.	1.0	46



#	ARTICLE	IF	CITATIONS
109	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2016, 39, 677-685.	4.3	46
110	Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. <i>European Journal of Heart Failure</i> , 2018, 20, 1106-1114.	2.9	45
111	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019, 21, 1571-1579.	2.9	44
112	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 895-902.	1.6	43
113	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 564-569.	1.9	43
114	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 315-322.	1.8	43
115	An <i>NPPB</i> Promoter Polymorphism Associated With Elevated N-Terminal pro-BNP Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
116	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2018, 3, 200.	3.0	41
117	Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e19.	1.3	40
118	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016, 37, 466-472.	1.0	40
119	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Nephilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.	1.6	40
120	Visualization, Quantification, and Alignment of Spectral Drift in Population Scale Untargeted Metabolomics Data. <i>Analytical Chemistry</i> , 2017, 89, 1399-1404.	3.2	39
121	Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. <i>Biostatistics</i> , 2015, 16, 60-72.	0.9	38
122	Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (<sc>ARIC</sc>) Study. <i>European Journal of Heart Failure</i> , 2016, 18, 629-637.	2.9	38
123	Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload. <i>JACC: Heart Failure</i> , 2017, 5, 157-165.	1.9	38
124	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. <i>JAMA Cardiology</i> , 2019, 4, 997.	3.0	38
125	Association of Left Atrial Structure and Function With Heart Failure in Older Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1549-1561.	1.2	38
126	Relationship Between Alcohol Consumption and Cardiac Structure and Function in the Elderly. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	36



#	ARTICLE	IF	CITATIONS
127	Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. <i>Diabetes Care</i> , 2020, 43, 2226-2233.	4.3	36
128	Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. <i>Circulation</i> , 2021, 144, e70-e91.	1.6	36
129	A Predictive Enrichment Procedure to Identify Potential Responders to a New Therapy for Randomized, Comparative Controlled Clinical Studies. <i>Biometrics</i> , 2016, 72, 877-887.	0.8	35
130	Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	35
131	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005288.	1.6	35
132	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1043-1052.	2.9	34
133	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 792-799.	2.9	34
134	Adiposity, body composition and ventricular arterial stiffness in the elderly: the Atherosclerosis Risk in Communities Study. <i>European Journal of Heart Failure</i> , 2018, 20, 1191-1201.	2.9	34
135	Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 970-976.	1.6	33
136	Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2016, 37, 2544-2551.	1.0	33
137	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. <i>American Journal of Medicine</i> , 2018, 131, 165-172.	0.6	33
138	Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 1203.	3.0	33
139	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1662-1671.	2.9	33
140	Excess mortality in solid organ transplant recipients hospitalized with COVID-19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19. <i>Clinical Transplantation</i> , 2022, 36, e14492.	0.8	33
141	Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. <i>Heart</i> , 2019, 105, 34-41.	1.2	32
142	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004457.	1.6	31
143	Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2015, 66, 429-440.	2.1	29
144	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 537-544.	1.2	29

#	ARTICLE	IF	CITATIONS
145	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e019545.	1.6	29
146	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016, 68, 873-881.	2.1	28
147	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 483-490.	2.9	28
148	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 1599-1601.	1.6	28
149	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
150	Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1129-1141.	2.9	27
151	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 372-381.	0.3	26
152	Spirolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Hypertension</i> , 2018, 31, 407-414.	1.0	26
153	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-9.	1.0	26
154	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021, 77, 546-556.	1.3	26
155	Trajectories of Blood Pressure Elevation Preceding Hypertension Onset. <i>JAMA Cardiology</i> , 2018, 3, 427.	3.0	25
156	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	24
157	Racial Disparities in Risks of Stroke. <i>New England Journal of Medicine</i> , 2017, 376, 2089-2090.	13.9	24
158	Widening Racial Differences in Risks for Coronary Heart Disease. <i>Circulation</i> , 2018, 137, 1195-1197.	1.6	24
159	Caffeine Consumption and Mortality in Diabetes: An Analysis of NHANES 1999-2010. <i>Frontiers in Endocrinology</i> , 2018, 9, 547.	1.5	24
160	Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, 355-368.	1.2	24
161	A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. <i>Statistics in Medicine</i> , 2015, 34, 3680-3695.	0.8	23
162	Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community. <i>JAMA Cardiology</i> , 2022, 7, 623.	3.0	23

#	ARTICLE	IF	CITATIONS
163	Meta-Analysis With Fixed, Unknown, Study-Specific Parameters. <i>Journal of the American Statistical Association</i> , 2014, 109, 1660-1671.	1.8	22
164	Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. <i>JAMA Cardiology</i> , 2018, 3, 357.	3.0	22
165	Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. <i>JACC: Heart Failure</i> , 2021, 9, 13-24.	1.9	22
166	Left Atrial Structure and Function Across the Spectrum of Cardiovascular Risk in the Elderly. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004010.	1.3	21
167	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 782-791.	1.9	21
168	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006125.	1.6	21
169	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019, 123, 611-617.	0.7	21
170	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in AHFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	1.9	21
171	Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. <i>European Journal of Heart Failure</i> , 2015, 17, 63-73.	2.9	20
172	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 155-164.	0.8	20
173	Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction. <i>JAMA Network Open</i> , 2019, 2, e195321.	2.8	20
174	Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. <i>Hypertension</i> , 2020, 76, 808-818.	1.3	20
175	Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. <i>Circulation</i> , 2021, 144, 177-179.	1.6	20
176	The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. <i>International Journal of Cardiology</i> , 2019, 284, 42-49.	0.8	19
177	Associations Between Depressive Symptoms and HFpEF-Related Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 1009-1020.	1.9	19
178	Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1211-1221.	1.2	19
179	Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans. <i>European Journal of Heart Failure</i> , 2021, 23, 1290-1295.	2.9	19
180	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	2.1	18

#	ARTICLE	IF	CITATIONS
181	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008293.	1.6	18
182	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 336-346.	1.9	18
183	Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1201-1209.	1.4	17
184	Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks. <i>JAMA Cardiology</i> , 2022, 7, 450.	3.0	17
185	Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. <i>BMJ Open</i> , 2022, 12, e059994.	0.8	17
186	A Pilot Study of Confocal Laser Endomicroscopy to Predict Barrier Dysfunction and Relapse in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 62, 873-878.	0.9	16
187	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020, 22, 1133-1143.	2.9	16
188	Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. <i>JAMA Cardiology</i> , 2021, 6, 509.	3.0	16
189	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 522-531.	2.1	15
190	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1560-1562.	1.6	15
191	Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2022, 10, 119-128.	1.9	15
192	Quantification of pleural effusions on thoracic ultrasound in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 513-521.	0.4	14
193	Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14
194	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. <i>Diabetologia</i> , 2018, 61, 581-588.	2.9	13
195	Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death. <i>Europace</i> , 2020, 22, 74-83.	0.7	13
196	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.	1.6	13
197	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13
198	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. <i>JACC: Heart Failure</i> , 2017, 5, 591-599.	1.9	12

#	ARTICLE	IF	CITATIONS
199	Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1554-1561.	0.9	12
200	Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy. <i>American Journal of Gastroenterology</i> , 2021, 116, 1638-1645.	0.2	12
201	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	3.0	12
202	Associations of Insulin Resistance With Systolic and Diastolic Blood Pressure: A Study From the HCHS/SOL. <i>Hypertension</i> , 2021, 78, 716-725.	1.3	12
203	Differential Influence of Distinct Components of Increased Blood Pressure on Cardiovascular Outcomes. <i>Hypertension</i> , 2013, 62, 492-498.	1.3	11
204	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy. <i>JACC: Heart Failure</i> , 2021, 9, 386-397.	1.9	11
205	Moving beyond our comfort zone. <i>European Heart Journal</i> , 2013, 34, 869-871.	1.0	10
206	Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. <i>Statistics in Medicine</i> , 2018, 37, 3589-3598.	0.8	10
207	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e008007.	1.6	10
208	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). <i>European Journal of Heart Failure</i> , 2021, 23, 1052-1056.	2.9	10
209	Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans. <i>Journal of the American College of Cardiology</i> , 2021, 78, 89-91.	1.2	10
210	Application of Optical Coherence Tomography Angiography Macular Analysis for Systemic Hypertension. A Systematic Review and Meta-analysis. <i>American Journal of Hypertension</i> , 2022, 35, 356-364.	1.0	10
211	Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry. <i>European Journal of Heart Failure</i> , 2022, 24, 1305-1315.	2.9	10
212	Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, .		10
213	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1895-1902.	1.1	9
214	Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 483-490.	2.1	9
215	Heart failure associated with imported malaria: a nationwide Danish cohort study. <i>ESC Heart Failure</i> , 2021, 8, 3521-3529.	1.4	9
216	Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life. <i>Journal of the American Heart Association</i> , 2021, 10, e020094.	1.6	9

#	ARTICLE	IF	CITATIONS
217	The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis. <i>Statistics in Biosciences</i> , 2017, 9, 284-297.	0.6	8
218	Change in Hemoglobin Trajectory and Darbeoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.	1.4	8
219	Towards personalized therapy for multiple sclerosis: limitations of observational data. <i>Brain</i> , 2018, 141, e38-e38.	3.7	8
220	Behind the Scenes of TOPCAT “ Bending to Inform. , 2022, 1, .		8
221	HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC Study. <i>Hypertension</i> , 2019, 73, 68-74.	1.3	7
222	Sex differences in congestive markers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021, 8, 1784-1795.	1.4	7
223	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. <i>PLoS Medicine</i> , 2020, 17, e1003361.	3.9	7
224	Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. <i>Journal of Cardiac Failure</i> , 2015, 21, S9-S10.	0.7	6
225	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	1.9	6
226	Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study. <i>Circulation: Heart Failure</i> , 2021, 14, e007891.	1.6	6
227	A-lines and B-lines in patients with acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 909-917.	0.4	6
228	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 10, 233-242.	0.8	5
229	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 11, 1-7.	0.8	5
230	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 815-816.	2.9	5
231	Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 387-397.	0.8	5
232	Postsystolic shortening on echocardiography as a gateway to cardiac computed tomography in patients with suspected stable angina pectoris. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 309-316.	0.7	5
233	Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn’s Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 677-685.	0.9	5
234	Influence of Study Discontinuation during the Run-in Period on the Estimated Efficacy of Sacubitril/valsartan in the PARAGON-HF Trial. <i>European Journal of Heart Failure</i> , 2021, , .	2.9	5



#	ARTICLE	IF	CITATIONS
235	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. <i>Statistics in Medicine</i> , 2021, 40, 6235-6242.	0.8	5
236	Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older Adults. <i>Journal of the American Heart Association</i> , 2022, 11, e022308.	1.6	5
237	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327.	1.6	5
238	Defining Study Outcomes That Better Reflect Individual Response to Treatment. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 258-262.	1.1	4
239	Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2022, , e021715.	1.6	4
240	Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC-ACS. <i>Journal of the American Heart Association</i> , 2022, 11, e024292.	1.6	4
241	Impact on survival of combination inhalers in patients with COPD at high risk of cardiovascular events. <i>International Journal of Cardiology</i> , 2020, 300, 237-244.	0.8	3
242	Temporal variations in the severity of COVID-19 illness by race and ethnicity. <i>BMJ Nutrition, Prevention and Health</i> , 2021, 4, 166-173.	1.9	3
243	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. <i>Journal of Cardiac Failure</i> , 2021, 27, 1382-1392.	0.7	3
244	Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events. <i>Blood</i> , 2017, 130, 685-685.	0.6	3
245	Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. <i>Diabetes Care</i> , 2022, 45, 2152-2155.	4.3	3
246	When the VEST Does Not Fit. <i>Circulation: Heart Failure</i> , 2018, 11, e005116.	1.6	2
247	Sex as a predictor of response to cancer immunotherapy. <i>Lancet Oncology</i> , The, 2018, 19, e377.	5.1	2
248	Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021, 335, 59-65.	0.8	2
249	Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 1128-1136.	0.7	2
250	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e349-e351.	0.6	1
251	Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1617.	3.4	1
252	CAD is a Risk Factor for Heart Failure with Preserved Ejection Fraction: The ARIC Study. <i>Journal of Cardiac Failure</i> , 2019, 25, S93.	0.7	1



#	ARTICLE	IF	CITATIONS
253	QuaLVAD Instrument: A New Measure of Quality of Life in Patients with a Left Ventricular Assist Device (LVAD). <i>Journal of Cardiac Failure</i> , 2019, 25, S156.	0.7	1
254	Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. <i>JAMA Surgery</i> , 2019, 154, 466.	2.2	1
255	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 175.	2.7	1
256	Sa1620 A Novel Upper Gastrointestinal Bleeding Score (AIMS65) Is More Accurate Than the Modified Blatchford Score in Predicting Mortality and Rebleeding. <i>Gastrointestinal Endoscopy</i> , 2011, 73, AB225-AB226.	0.5	0
257	Reply: The Association between Obstructive Sleep Apnea Severity and N-Terminal Pro-B-Type Natriuretic Peptide Levels in Women. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 869-870.	2.5	0
258	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1535-1536.	1.2	0
259	Response to Letter Regarding Article, "Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study". <i>Circulation: Heart Failure</i> , 2015, 8, 1010-1010.	1.6	0
260	Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2016, 22, S65-S66.	0.7	0
261	Sacubitril/Valsartan Associated with Lower Declines in Health-Related Quality of Life Compared with Enalapril in Patients with Heart Failure Hospitalization. <i>Journal of Cardiac Failure</i> , 2016, 22, S24.	0.7	0
262	Association between Baseline, and Changes in, Health-Related Quality of Life and Death and HF Hospitalization in PARADIGM-HF. <i>Journal of Cardiac Failure</i> , 2016, 22, S92.	0.7	0
263	Sacubitril/valsartan in PARADIGM-HF " Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 496.	5.5	0
264	SEX AND RACE DIFFERENCES IN CIRCULATING LEVELS OF NATRIURETIC PEPTIDE CONCENTRATIONS AND THE ASSOCIATION WITH INCIDENT HEART FAILURE IN THE COMMUNITY: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 911.	1.2	0
265	UTILITY OF BASELINE AND FOLLOW-UP CARDIOVASCULAR PHYSICAL EXAMS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: TOPCAT. <i>Journal of the American College of Cardiology</i> , 2019, 73, 712.	1.2	0
266	Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". <i>Circulation</i> , 2019, 139, 422-423.	1.6	0
267	Myocardial performance index is associated with cardiac computed tomography findings in patients with suspected coronary artery disease. <i>Echocardiography</i> , 2020, 37, 1741-1748.	0.3	0
268	Response to Cheng et al.. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, .	0.2	0
269	Title is missing!. , 2020, 17, e1003361.		0
270	Title is missing!. , 2020, 17, e1003361.		0

#	ARTICLE	IF	CITATIONS
271	Title is missing!. , 2020, 17, e1003361.		0
272	Title is missing!. , 2020, 17, e1003361.		0
273	Title is missing!.. , 2020, 17, e1003361.		0
274	Left atrial inflow propagation velocity derived by color M-mode Doppler in acute heart failure. International Journal of Cardiovascular Imaging, 2022, 38, 2155-2165.	0.2	0